Introduction to Pliant Therapeutics' Participation
Pliant Therapeutics, Inc. (NASDAQ: PLRX), a dedicated force in the clinical-stage biotechnology sector, is set to make waves at an upcoming healthcare conference. The event serves as a platform for the company to showcase its integrin-based therapeutics—game-changing innovations aimed at treating various serious health conditions.
Event Details for the Piper Sandler Healthcare Conference
The Piper Sandler 37th Annual Healthcare Conference, taking place from December 2 to December 4, provides a unique opportunity for Pliant Therapeutics to connect with investors and emphasize its commitment to developing breakthrough therapies. Dr. Bernard Coulie, the company's President and Chief Executive Officer, alongside other key executives like Dr. Keith Cummings, Chief Financial Officer, and Dr. Éric Lefebvre, Chief Medical Officer, will engage in an insightful fireside chat. This session is scheduled for December 4 at 12:30 p.m. Eastern Time, and it's expected to attract significant attention from industry stakeholders.
Accessing Conference Insights
For those interested in following along, Pliant Therapeutics encourages attendees to tune into the live webcast of the fireside chat. You can find it through the company’s dedicated event page, where insights post-event will also be preserved in an archived format for 90 days.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is on a mission to transform healthcare through integrin-based therapeutics. Currently, the company’s pipeline features PLN-101095, a cutting-edge small molecule that acts as a dual-selective inhibitor of integrin ?v?8 and ?v?1, designed to address solid tumors. This pioneering approach aligns with the industry's growing trend toward targeted therapies, promising increased efficacy and fewer side effects.
Expanding Pipeline and Future Prospects
Furthermore, Pliant has embarked on an ambitious journey with PLN-101325, a monoclonal antibody agonist that targets integrin ?7?1 and aims to improve treatments for muscular dystrophies. The robust early-stage platform showcases Pliant's ongoing commitment to maximize therapeutic delivery via integrin receptor-binding methodologies.
Engagement with the Community and Stakeholders
As Pliant Therapeutics continues to push boundaries in biopharmaceuticals, the firm prioritizes transparent communication with its shareholders and the public. The company actively maintains an online presence, inviting interested parties to follow their advancements through popular social media platforms like LinkedIn, Facebook, and X.
Investor and Media Contact
To facilitate open lines of communication, Christopher Keenan holds the position of Vice President of Investor Relations and Corporate Communications. For media inquiries or investor relations, Christopher can be reached via email at ir@pliantrx.com.
Frequently Asked Questions
What is Pliant Therapeutics focused on?
Pliant Therapeutics is focused on the discovery and development of integrin-based therapeutics aimed at treating serious health conditions, including solid tumors and muscular dystrophies.
When is Pliant participating in the Piper Sandler Conference?
Pliant Therapeutics will participate in the Piper Sandler Healthcare Conference from December 2 to December 4, with a fireside chat scheduled for December 4 at 12:30 p.m. Eastern Time.
How can I access the fireside chat?
The fireside chat can be accessed through Pliant Therapeutics’ event page, where a replay will also be available for 90 days following the event.
Who are the key executives speaking at the conference?
The conference will feature Dr. Bernard Coulie, Dr. Keith Cummings, and Dr. Éric Lefebvre from Pliant Therapeutics discussing insights into their ongoing projects.
What are Pliant's key products in development?
Pliant is developing PLN-101095 and PLN-101325, targeting solid tumors and muscular dystrophies, respectively, as part of their innovative therapeutic landscape.
